Ascenta Capital

Ascenta Capital is a private equity and venture capital firm established in 2023 and based in New York, New York. The firm focuses on investing in the biotechnology sector, aiming to support innovative companies that are developing transformative technologies and solutions in healthcare. Through its investments, Ascenta Capital seeks to foster growth and advancement in the biotech industry, contributing to the development of new therapies and medical advancements.

Lorence Kim MD

Co-Founder and Managing Partner

Evan Rachlin MD

Co-Founder and Managing Partner

2 past transactions

OrsoBio

Series B in 2024
OrsoBio is a clinical-stage biopharmaceutical company focused on developing innovative therapies to treat severe metabolic disorders such as obesity, type 2 diabetes, lipodystrophies, and severe dyslipidemia. The company aims to restore energy homeostasis in patients by targeting pathways relevant to maintaining energy balance, thereby addressing the root causes of these conditions. OrsoBio's pipeline includes therapies intended to revolutionize the treatment of these disorders.

ADARx Pharmaceuticals

Series B in 2023
ADARx Pharmaceuticals, Inc. is a clinical-stage biotechnology company based in San Diego, California, focused on the research and development of RNA editing therapeutics. Established in 2019, the company specializes in genetic medicine by utilizing a proprietary platform that employs endogenous enzymes, specifically adenosine deaminase acting on RNA (ADAR), to precisely target and correct single point mutations in RNA transcripts. This innovative approach aims to restore the production of functional proteins, offering potential treatments for a variety of diseases, including those affecting genetic, cardiometabolic, complement-mediated, and central nervous system areas. ADARx Pharmaceuticals is dedicated to developing life-saving therapeutics that address genetic mutations and provide solutions for conditions that are currently considered incurable.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.